Core Viewpoint - Biohaven's experimental depression drug failed to meet primary goals in mid-stage trials, leading to a nearly 14% pre-market drop in stock price to $9.31 [1] Group 1: Clinical Trial Results - The drug BHV-7000 did not show significant improvement in depressive symptoms compared to a placebo in a six-week trial involving patients with severe depression [1] - The company considers the subgroup analysis for depression as "hypothetical exploration" and does not plan to conduct further psychiatric clinical trials [1] Group 2: Strategic Focus - Biohaven intends to concentrate resources on key priority areas such as immunology, obesity, and epilepsy, aiming for a shift in focus by 2026 [1]

Group 1 - Biohaven's experimental depression drug failed to meet primary endpoints in a mid-stage trial, contributing to a stock price drop of 16% in after-hours trading and an overall decline of over 70% this year [1] - The company previously faced a clinical trial failure in March and a rejection from U.S. regulators for its drug Troriluzole, intended for treating a rare neurodegenerative disease [1] - In a six-week trial for patients with major depressive disorder, Biohaven's drug BHV-7000 did not show significant differences in depression symptom reduction compared to a placebo [1] Group 2 - Biohaven plans to focus resources on key priority areas such as immunology, obesity, and epilepsy by 2026, and will not pursue additional psychiatric clinical trials [1] - Analyst Leonid Tsymashev noted that the trial failure was not surprising given the limited clinical efficacy data and the challenges associated with major depressive disorder [1] - Following the FDA's rejection of Troriluzole, Biohaven announced a plan to cut annual direct R&D spending by approximately 60% [2]

Core Viewpoint - Company received approval from the National Medical Products Administration for clinical trials of a new production process for intravenous immunoglobulin (pH4), enhancing product quality and safety [1] Group 1: Clinical Trial Approval - Guangdong Shuanglin Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has been granted a clinical trial approval notice (No. 2025LP03518) [1] - The approval allows the company to conduct clinical trials for the new production process of intravenous immunoglobulin (pH4) [1] Group 2: Production Process Change - The production process has shifted from traditional low-temperature ethanol protein separation to an internationally mainstream method involving caprylic acid precipitation and multi-step chromatography purification [1] - This change is expected to significantly improve product quality, virus safety, and yield [1] Group 3: Market Competitiveness - The new production process will enhance the safety and convenience of clinical use, aligning domestic product standards with international levels [1] - The upgrade in production technology is anticipated to strengthen the market competitiveness of the company's fourth-generation intravenous immunoglobulin products [1]

Core Viewpoint - Sanofi's subsidiary, Sirnaomics, Inc., has completed the Phase I trial of the investigational drug STP707 and has formally submitted the clinical research report to the FDA [1] Group 1: Clinical Trial Details - The Phase I trial included adults with advanced, metastatic, or unresectable solid tumors that had progressed or were unresponsive to standard treatments [1] - STP707 demonstrated clinical activity in these patients, with some achieving disease stabilization and delaying disease progression in a population with limited treatment options [1] - Patients received different doses of STP707 via intravenous administration, with most side effects being manageable [1] Group 2: Regulatory and Development Plans - The completion of the Phase I trial and submission of the clinical research report is considered a key milestone for STP707 [1] - Following the submission, Sirnaomics, Inc. is preparing to initiate discussions with the FDA to determine the strategy for Phase II development [1]

Group 1: Drug Approvals and Clinical Trials - AstraZeneca and Daiichi Sankyo's drug combination Enhertu and Perjeta received FDA approval as a first-line treatment for HER2-positive metastatic breast cancer, marking the first new first-line therapy in over a decade, showing a 44% reduction in disease progression or death risk compared to traditional THP therapy [1] - Takeda's oral TYK2 inhibitor zasocitinib demonstrated strong performance in two Phase III trials for moderate to severe plaque psoriasis, with over 75% improvement in key metrics after 16 weeks, and plans to submit for FDA approval in 2026 [2] Group 2: Clinical Trial Setbacks - Daiichi Sankyo's ADC drug ifinatamab deruxtecan has paused patient recruitment in its global Phase III trial due to unexpected interstitial lung disease deaths, which affects its accelerated approval plans based on Phase II data [1] Group 3: Mergers and Acquisitions - Fosun Pharma plans to acquire a 53% stake in Green Valley Pharmaceutical for approximately $200 million to revive the controversial Alzheimer's drug GV-971, which did not receive regulatory renewal in China [4] - Harbour BioMed entered into a collaboration agreement with Bristol-Myers Squibb worth up to $1.1 billion, including an initial payment of $90 million, for a multispecific antibody [5] - Sanofi signed two biotechnology collaboration agreements, including a deal worth up to $1.04 billion for the Alzheimer's candidate ADEL-Y01, with an initial payment of $80 million [6] Group 4: Regulatory Changes - The U.S. Congress passed the revised Biosecure Act as part of the annual defense bill, which is expected to raise entry barriers for Chinese life sciences companies into the U.S. market [3]

Core Viewpoint - The announcement indicates that the company's subsidiary, Yabao Biotech, has received approval from the National Medical Products Administration for the clinical trial of GLX002, a modified new drug based on bosentan dispersible tablets, aimed at treating pulmonary arterial hypertension (PAH) [1] Group 1: Product Details - GLX002 is designed for patients aged 1 year and older with idiopathic or congenital PAH, targeting improvements in pulmonary vascular resistance (PVR) [1] - The drug is intended to enhance exercise capacity in adult patients with WHO functional class II-IV PAH [1] Group 2: Regulatory Approval - The approval from the National Medical Products Administration is a significant milestone for the company, allowing it to proceed with clinical trials for GLX002 [1]

Core Viewpoint - Company Cloudbreak USA successfully held a Phase 2 clinical trial meeting with the FDA regarding CBT-004, a preservative-free eye drop intended for treating vascularized eyelid lesions, marking significant progress in its clinical development [1][2] Group 1: Clinical Trial Results - The Phase 2 clinical trial meeting was based on results completed in May 2025, showing that CBT-004 is safe and well-tolerated, achieving primary and several secondary efficacy endpoints [2] - CBT-004 demonstrated efficacy in reducing conjunctival hyperemia, with effects observable as early as 7 days after the first dose [2] - During the 28-day treatment period, improvements were noted in symptoms such as burning or stinging, itching, and foreign body sensation, with some effects persisting significantly for 4 weeks post-treatment [2] Group 2: FDA Feedback and Next Steps - The FDA provided feedback on drug stability, specifications research, and non-clinical studies required for the New Drug Application (NDA), as well as the design and endpoints for the Phase 3 clinical study [1] - A consensus was reached with the FDA to use the reduction of hyperemia symptoms as the primary endpoint for CBT-004's approval, with symptom relief as a potential co-primary endpoint [1][2] - The successful Phase 2 clinical trial meeting is seen as a major step towards advancing CBT-004 into Phase 3 clinical research, paving the way for its NDA and subsequent commercialization [2]

Group 1 - The company announced that some of its products have been included in the 2025 National Medical Insurance Directory, which is expected to enhance market expansion and product sales [1][2] - The innovative drug Aibegersitin α injection and the imported product Dihyaluronic Acid Sodium Injection have been renewed for inclusion, while the compound Huangdai Tablets have been adjusted to the regular national medical insurance directory [1] - The 2025 National Medical Insurance Directory will be officially implemented on January 1, 2026, with specific reimbursement standards and details to be announced by relevant government departments [2] Group 2 - The company’s subsidiary Hefei Xinzhu Biotechnology has received approval for clinical trials of the innovative macromolecule drug N-3C01 injection, targeting advanced solid tumors and non-muscle invasive bladder cancer [4][5] - N-3C01 is a recombinant IL-15/IL-15Rα fusion protein designed to activate immune cells for tumor destruction, showing promising preclinical results in activating NK cells and CD8+ T cells [6] - The approval for clinical trials indicates that the drug meets the necessary requirements for drug registration, although further steps are needed before it can be marketed [5][6]

As filed with the Securities and Exchange Commission on December 8, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GRI BIO, INC. (Exact name of registrant as specified in its charter) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) (State or other jurisdiction of incorporation or organization) 2223 Avenida de la Playa, #208 La Jolla, CA 92037 ...

Core Viewpoint - The company announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for the GB10 injection, aimed at treating neovascular age-related macular degeneration (nAMD) [1] Group 1 - The NMPA has issued a "Clinical Trial Approval Notification" for the GB10 injection [1] - The clinical trial application for GB10 injection meets the relevant requirements for drug registration [1] - The clinical trial will focus on treating neovascular age-related macular degeneration (nAMD) [1]